卡培他滨在晚期消化系统肿瘤一线联合化疗中的应用  

Capectabine in combination with other chemotherapy as first-line in gastrointestinal cancer

作　　者：甄振华[1] 陶雄飞[1] 李心忠[1] 申传厚[1] 詹必红[1] 

机构地区：[1]安徽省淮北市人民医院肿瘤科,安徽淮北235000

出　　处：《现代肿瘤医学》2010年第10期2004-2006,共3页Journal of Modern Oncology

摘　　要：目的:评估卡培他滨联合其他化疗药物治疗消化系统肿瘤的疗效和安全性。方法:回顾性分析卡培他滨联合其他化疗药物治疗28例晚期大肠癌、9例进展期胃癌和4例晚期食管癌的疗效和不良反应。结果:全组可评价疗效41例,其中CR 3例,PR 18例,SD 10例,PD 10例,有效率(RR)51.2%,疾病控制率(DC)为75.6%,中位无进展生存期(PFS)7.1个月,中位生存时间(OS)14.5个月。不良反应以消化道症状、粒细胞下降、手足综合症最为多见。结论:卡培他滨联合其他化疗药物一线治疗晚期消化道肿瘤有较高的有效率和疾病控制率,不良反应轻微,患者可耐受。Objective：To evaluate the efficacy and safety of capectabine for gastrointestinal cancer.Methods：Data of 28 metastatic colorectal cancers（mCRC）,9 advanced gastric cancers（AGC）,and 4 metastatic esophageal cancers treated with capectabine in combination with other chemotherapy were retrospe-ctively reviewed,and the efficacy and adverse events were analyzed.Results：Total of 41 patients were evaluable.There were 3 CR,8 PR,10 SD and 10 PD,with the responserate（RR） of 51.2% and the disease control rate（DC） of 75.6%.The median PFS was 7.1 months,and the median OS was 14.5 months.The major toxicity included gastrointestinal reaction,neutropenia,hand-food syndromed.Conclusion：Capecitab-ine plus other chemotherapy is effective as the first-line chemotherapy for gastro-intestinal cancer.The adverse effects are mild and tolerable.

关 键 词：卡培他滨 晚期大肠癌 进展期胃癌 化疗 

分 类 号：R735[医药卫生—肿瘤]